Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more
Gemina Laboratories Ltd (GLABF) - Total Assets
Latest total assets as of January 2025: $1.44 Million USD
Based on the latest financial reports, Gemina Laboratories Ltd (GLABF) holds total assets worth $1.44 Million USD as of January 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gemina Laboratories Ltd - Total Assets Trend (2021–2025)
This chart illustrates how Gemina Laboratories Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Gemina Laboratories Ltd - Asset Composition Analysis
Current Asset Composition (January 2025)
Gemina Laboratories Ltd's total assets of $1.44 Million consist of 7.4% current assets and 92.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Gemina Laboratories Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gemina Laboratories Ltd's current assets represent 7.4% of total assets in 2025, a decrease from 96.8% in 2021.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 34.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Gemina Laboratories Ltd Competitors by Total Assets
Key competitors of Gemina Laboratories Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Gemina Laboratories Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Gemina Laboratories Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Gemina Laboratories Ltd is currently not profitable relative to its asset base.
Gemina Laboratories Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.03 | 0.82 |
| Quick Ratio | 0.02 | 0.03 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.59 Million | $ -2.74 Million | $ -505.10K |
Gemina Laboratories Ltd - Advanced Valuation Insights
This section examines the relationship between Gemina Laboratories Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 343.96 |
| Latest Market Cap to Assets Ratio | 23.84 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | $1.44 Million |
| Market Capitalization | $34.29 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Gemina Laboratories Ltd's assets at a significant premium ( 23.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Gemina Laboratories Ltd's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Gemina Laboratories Ltd (2021–2025)
The table below shows the annual total assets of Gemina Laboratories Ltd from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-01-31 | $1.44 Million | -1.24% |
| 2024-01-31 | $1.46 Million | -22.33% |
| 2023-01-31 | $1.87 Million | +32.03% |
| 2022-01-31 | $1.42 Million | -43.80% |
| 2021-01-31 | $2.53 Million | -- |